A citation-based method for searching scientific literature

Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne M de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan de Hoon, William Smith, Kathryn E Stephenson, Stephen C De Rosa, Kristen W Cohen, M Juliana McElrath, Emmanuel Cormier, Gert Scheper, Dan H Barouch, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, Hanneke Schuitemaker. N Engl J Med 2021
Times Cited: 509







List of co-cited articles
757 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P Polack, Stephen J Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L Perez, Gonzalo Pérez Marc, Edson D Moreira, Cristiano Zerbini,[...]. N Engl J Med 2020
67

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R Baden, Hana M El Sahly, Brandon Essink, Karen Kotloff, Sharon Frey, Rick Novak, David Diemert, Stephen A Spector, Nadine Rouphael, C Buddy Creech,[...]. N Engl J Med 2021
64

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, Lily Y Weckx, Pedro M Folegatti, Parvinder K Aley, Brian Angus, Vicky L Baillie, Shaun L Barnabas, Qasim E Bhorat,[...]. Lancet 2021
37

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Pedro M Folegatti, Katie J Ewer, Parvinder K Aley, Brian Angus, Stephan Becker, Sandra Belij-Rammerstorfer, Duncan Bellamy, Sagida Bibi, Mustapha Bittaye, Elizabeth A Clutterbuck,[...]. Lancet 2020
31

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev, Beatriz Grinsztejn, Paul A Goepfert, Carla Truyers, Hein Fennema, Bart Spiessens,[...]. N Engl J Med 2021
681
23

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Cheryl Keech, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed, Susan Neal, Joyce S Plested, Mingzhu Zhu, Shane Cloney-Clark, Haixia Zhou,[...]. N Engl J Med 2020
532
22

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y Logunov, Inna V Dolzhikova, Dmitry V Shcheblyakov, Amir I Tukhvatulin, Olga V Zubkova, Alina S Dzharullaeva, Anna V Kovyrshina, Nadezhda L Lubenets, Daria M Grousova, Alina S Erokhova,[...]. Lancet 2021
610
22

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
Lisa A Jackson, Evan J Anderson, Nadine G Rouphael, Paul C Roberts, Mamodikoe Makhene, Rhea N Coler, Michele P McCullough, James D Chappell, Mark R Denison, Laura J Stevens,[...]. N Engl J Med 2020
20

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Maheshi N Ramasamy, Angela M Minassian, Katie J Ewer, Amy L Flaxman, Pedro M Folegatti, Daniel R Owens, Merryn Voysey, Parvinder K Aley, Brian Angus, Gavin Babbage,[...]. Lancet 2021
580
20

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, Weixiao Han, Zhen Chen, Rong Tang, Weidong Yin,[...]. Lancet Infect Dis 2021
504
20

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Shengli Xia, Yuntao Zhang, Yanxia Wang, Hui Wang, Yunkai Yang, George Fu Gao, Wenjie Tan, Guizhen Wu, Miao Xu, Zhiyong Lou,[...]. Lancet Infect Dis 2021
404
18

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jing-Xin Li, Bei-Fang Yang, Ling Wang, Wen-Juan Wang,[...]. Lancet 2020
567
18

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Edward E Walsh, Robert W Frenck, Ann R Falsey, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Mark J Mulligan, Ruth Bailey,[...]. N Engl J Med 2020
18

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Denis Y Logunov, Inna V Dolzhikova, Olga V Zubkova, Amir I Tukhvatullin, Dmitry V Shcheblyakov, Alina S Dzharullaeva, Daria M Grousova, Alina S Erokhova, Anna V Kovyrshina, Andrei G Botikov,[...]. Lancet 2020
441
17

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
Shabir A Madhi, Vicky Baillie, Clare L Cutland, Merryn Voysey, Anthonet L Koen, Lee Fairlie, Sherman D Padayachee, Keertan Dheda, Shaun L Barnabas, Qasim E Bhorat,[...]. N Engl J Med 2021
534
15

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
David S Khoury, Deborah Cromer, Arnold Reynaldi, Timothy E Schlub, Adam K Wheatley, Jennifer A Juno, Kanta Subbarao, Stephen J Kent, James A Triccas, Miles P Davenport. Nat Med 2021
887
15

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Shengli Xia, Kai Duan, Yuntao Zhang, Dongyang Zhao, Huajun Zhang, Zhiqiang Xie, Xinguo Li, Cheng Peng, Yanbo Zhang, Wei Zhang,[...]. JAMA 2020
330
14

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Daniel Wrapp, Nianshuang Wang, Kizzmekia S Corbett, Jory A Goldsmith, Ching-Lin Hsieh, Olubukola Abiona, Barney S Graham, Jason S McLellan. Science 2020
14

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Feng-Cai Zhu, Yu-Hua Li, Xu-Hua Guan, Li-Hua Hou, Wen-Juan Wang, Jing-Xin Li, Shi-Po Wu, Bu-Sen Wang, Zhao Wang, Lei Wang,[...]. Lancet 2020
664
13

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Evan J Anderson, Nadine G Rouphael, Alicia T Widge, Lisa A Jackson, Paul C Roberts, Mamodikoe Makhene, James D Chappell, Mark R Denison, Laura J Stevens, Andrea J Pruijssers,[...]. N Engl J Med 2020
653
11

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
Andreas Greinacher, Thomas Thiele, Theodore E Warkentin, Karin Weisser, Paul A Kyrle, Sabine Eichinger. N Engl J Med 2021
869
11

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Paul T Heath, Eva P Galiza, David N Baxter, Marta Boffito, Duncan Browne, Fiona Burns, David R Chadwick, Rebecca Clark, Catherine Cosgrove, James Galloway,[...]. N Engl J Med 2021
178
11

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni, Daniela Weiskopf, Sydney I Ramirez, Jose Mateus, Jennifer M Dan, Carolyn Rydyznski Moderbacher, Stephen A Rawlings, Aaron Sutherland, Lakshmanane Premkumar, Ramesh S Jadi,[...]. Cell 2020
11

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche,[...]. Cell 2020
11

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Mark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Vanessa Raabe, Ruth Bailey, Kena A Swanson,[...]. Nature 2020
659
11

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Jennifer M Dan, Jose Mateus, Yu Kato, Kathryn M Hastie, Esther Dawen Yu, Caterina E Faliti, Alba Grifoni, Sydney I Ramirez, Sonya Haupt, April Frazier,[...]. Science 2021
11

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Raches Ella, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal,[...]. Lancet Infect Dis 2021
121
10

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, Xin Fang, Chenfei Wang, Xiang Zhao, Enqi Huang,[...]. Lancet Infect Dis 2021
123
10

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, Lily Y Weckx, Pedro M Folegatti, Parvinder K Aley, Brian Angus, Vicky L Baillie, Shaun L Barnabas, Qasim E Bhorat,[...]. Lancet 2021
442
10

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
Mine Durusu Tanriover, Hamdi Levent Doğanay, Murat Akova, Hatice Rahmet Güner, Alpay Azap, Sıla Akhan, Şükran Köse, Fatma Şebnem Erdinç, Emin Halis Akalın, Ömer Fehmi Tabak,[...]. Lancet 2021
164
10

A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Peng Zhou, Xing-Lou Yang, Xian-Guang Wang, Ben Hu, Lei Zhang, Wei Zhang, Hao-Rui Si, Yan Zhu, Bei Li, Chao-Lin Huang,[...]. Nature 2020
10

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, Eileen Gallagher, Ruth Simmons, Simon Thelwall, Julia Stowe, Elise Tessier, Natalie Groves, Gavin Dabrera,[...]. N Engl J Med 2021
852
10

A Novel Coronavirus from Patients with Pneumonia in China, 2019.
Na Zhu, Dingyu Zhang, Wenling Wang, Xingwang Li, Bo Yang, Jingdong Song, Xiang Zhao, Baoying Huang, Weifeng Shi, Roujian Lu,[...]. N Engl J Med 2020
10

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.
Rinke Bos, Lucy Rutten, Joan E M van der Lubbe, Mark J G Bakkers, Gijs Hardenberg, Frank Wegmann, David Zuijdgeest, Adriaan H de Wilde, Annemart Koornneef, Annemiek Verwilligen,[...]. NPJ Vaccines 2020
70
14

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Peter Richmond, Lara Hatchuel, Min Dong, Brenda Ma, Branda Hu, Igor Smolenov, Ping Li, Peng Liang, Htay Htay Han, Joshua Liang,[...]. Lancet 2021
111
10

Correlates of protection against SARS-CoV-2 in rhesus macaques.
Katherine McMahan, Jingyou Yu, Noe B Mercado, Carolin Loos, Lisa H Tostanoski, Abishek Chandrashekar, Jinyan Liu, Lauren Peter, Caroline Atyeo, Alex Zhu,[...]. Nature 2021
412
9

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu,[...]. Lancet 2020
9

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Lee Fairlie, Umesh Lalloo, Mduduzi S L Masilela, Dhayendre Moodley, Sherika Hanley,[...]. N Engl J Med 2021
220
9

Remdesivir for the Treatment of Covid-19 - Final Report.
John H Beigel, Kay M Tomashek, Lori E Dodd, Aneesh K Mehta, Barry S Zingman, Andre C Kalil, Elizabeth Hohmann, Helen Y Chu, Annie Luetkemeyer, Susan Kline,[...]. N Engl J Med 2020
8

SARS-CoV-2 vaccines in development.
Florian Krammer. Nature 2020
794
8

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Galit Alter, Jingyou Yu, Jinyan Liu, Abishek Chandrashekar, Erica N Borducchi, Lisa H Tostanoski, Katherine McMahan, Catherine Jacob-Dolan, David R Martinez, Aiquan Chang,[...]. Nature 2021
103
8

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
Kathryn E Stephenson, Mathieu Le Gars, Jerald Sadoff, Anne Marit de Groot, Dirk Heerwegh, Carla Truyers, Caroline Atyeo, Carolin Loos, Abishek Chandrashekar, Katherine McMahan,[...]. JAMA 2021
107
8

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
Noe B Mercado, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, Katherine McMahan, Lisa H Tostanoski,[...]. Nature 2020
483
8

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.
Rinke Bos, Lucy Rutten, Joan E M van der Lubbe, Mark J G Bakkers, Gijs Hardenberg, Frank Wegmann, David Zuijdgeest, Adriaan H de Wilde, Annemart Koornneef, Annemiek Verwilligen,[...]. NPJ Vaccines 2020
132
8

Evidence for antibody as a protective correlate for COVID-19 vaccines.
Kristen A Earle, Donna M Ambrosino, Andrew Fiore-Gartland, David Goldblatt, Peter B Gilbert, George R Siber, Peter Dull, Stanley A Plotkin. Vaccine 2021
219
8

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhiwei Wu, Yaling Hu, Miao Xu, Zhen Chen, Wanqi Yang, Zhiwei Jiang, Minjie Li, Hui Jin, Guoliang Cui, Panpan Chen,[...]. Lancet Infect Dis 2021
169
8

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
Carolyn Rydyznski Moderbacher, Sydney I Ramirez, Jennifer M Dan, Alba Grifoni, Kathryn M Hastie, Daniela Weiskopf, Simon Belanger, Robert K Abbott, Christina Kim, Jinyong Choi,[...]. Cell 2020
630
8

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
Stephen J Thomas, Edson D Moreira, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L Perez, Gonzalo Pérez Marc, Fernando P Polack, Cristiano Zerbini,[...]. N Engl J Med 2021
250
8

Neutralizing Activity of BNT162b2-Elicited Serum.
Yang Liu, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R Fontes-Garfias, Kena A Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler,[...]. N Engl J Med 2021
286
8

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Xinxue Liu, Robert H Shaw, Arabella S V Stuart, Melanie Greenland, Parvinder K Aley, Nick J Andrews, J Claire Cameron, Sue Charlton, Elizabeth A Clutterbuck, Andrea M Collins,[...]. Lancet 2021
114
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.